<DOC>
	<DOCNO>NCT01781936</DOCNO>
	<brief_summary>The purpose study determine tolerability , safety , benefit investigational drug , Fluocinolone Acetonide Intravitreal Insert ( FA-i ) , people posterior uveitis . The study drug , Fluocinolone Acetonide , currently use surgical implant , Retisert , approve U.S. Food Drug Administration ( FDA ) treat non-infectious posterior uveitis . The study drug able insert ophthalmology ( eye ) clinic ; whereas Retisert must surgically implant Operating Room . Initially , 2-dose randomize pilot study . However , study modify include 0.2 ug/day implant .</brief_summary>
	<brief_title>Pilot Study Fluocinolone Acetonide Intravitreal Insert ( FA-i ) Treat Intermediate- , Posterior- , Panuveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>1 . At least 18 year old time consent . 2 . One eye minimum 1 year history recurrent noninfectious uveitis affect posterior segment require either ) systemic corticosteroid equivalent nonsteroidal immunosuppressive agent give least 3 month prior enrollment OR least 2 subTenon 's injection corticosteroid management uveitis 6 month prior enrollment OR least 2 separate recurrence uveitis within 6 month prior enrollment require systemic , intravitreal subTenon 's injection corticosteroid OR recurrence uveitis receive intravitreal steroid implant ( Ozurdex Retisert ) OR recurrence uveitis receive FAi ( Fluocinolone Acetonide intravitreal insert ) . 3 . Negative serum pregnancy test baseline woman childbearing potential . 4 . An informed consent document sign date subject legally acceptable representative . 5 . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . 6 . Unable tolerate side effect therapy systemic corticosteroid equivalent nonsteroidal immunosuppressive agent Subjects present follow include study : 1 . History glaucoma study eye 2 . Allergy corticosteroid component delivery system 3 . History iridocyclitis vitreous cell vitreous haze study eye 4 . Uveitis infectious etiology study eye 5 . Vitreous hemorrhage study eye 6 . Toxoplasmosis scar study eye 7 . Media opacity preclude evaluation retina vitreous study eye 8 . Peripheral retinal detachment area insertion study eye 9 . Elevated Intraocular pressure ( IOP ) &gt; 21 1 antiocular hypertensive medication study eye 10 . History elevate IOP ( Intraocular Pressure ) ( 22 mmHg ) study eye corticosteroid unless subject previously undergone filtration surgery ( tube shunt trabeculectomy ) follow episode steroidassociated ocular hypertension . In latter case , subject eligible enrollment , provide intraocular pressure control &lt; 21 mmHg one antiocular hypertensive medication . 11 . Ocular surgery study eye within 3 month prior enrollment require chronic systemic therapy 12 . Systemic immunosuppressive therapy manage nonocular disease 13 . Patients test positive human immune deficiency virus 14 . Pregnant females 15 . Patients protocol procedure may pose special risk outweigh potential benefit participate study 16 . Patients unlikely comply study protocol 17 . Any severe acute chronic medical psychiatric condition could increase risk associate study participation could interfere interpretation study result , judgment investigator , could make patient inappropriate entry study . 18 . Treatment investigational drug device study eye within 30 day precede device placement . 19 . Females childbearing potential unwilling unable use acceptable method contraception outline protocol least 14 day prior first dose study medication throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>